Indapta Therapeutics
Overview
Indapta Therapeutics is a biotechnology company specializing in the development and commercialization of an allogeneic FcRγ-deficient natural killer (G-NK) cell therapy aimed at treating various types of cancer. Founded in 2016, Indapta is headquartered in Houston, TX, and Seattle, WA. It was co-founded by Guy DiPierro and Ronald Martell. As of 2024, the company raised over $72.5 million in funding, notably completing a $22.5 million round in December 2024.
Recent Developments
- December 2024: Indapta Therapeutics secured $22.5 million to advance clinical trials of its innovative cancer and autoimmune treatments. This funding round involved current investors such as RA Capital Management, Leaps by Bayer, and the Myeloma Investment Fund. The financing is directed towards generating significant data from ongoing trials, including the initiation of a Phase 1 trial for multiple sclerosis in early 2025.
- November 2024: The company presented significant clinical and preclinical data at the Society for Immunotherapy of Cancer meeting in Houston. The data demonstrated positive clinical activity with its IDP-023 therapy in relapsed/refractory multiple myeloma, observing substantial response rates even at the lowest dosage without a monoclonal antibody target.
- August 2024: Indapta received FDA clearance to commence a Phase 1 trial evaluating its g-NK cell therapy, IDP-023, targeting progressive multiple sclerosis. This initiative bolsters Indapta's differentiated approach to treating autoimmune diseases alongside cancers.
- Indapta's ongoing collaboration with Sanofi aims to evaluate the efficacy of combining its g-NK cell therapy with Sanofi's Sarclisa in multiple myeloma cases, showcasing a strategic partnership to extend the therapeutic reach of Indapta's platform.
- May 2024: The Cancer Prevention and Research Institute of Texas awarded Indapta a $4.5 million grant to advance clinical trials for its g-NK cell therapy in lymphoma and multiple myeloma patients.
Company Information
| Attribute | Information |
|---|---|
| Founding Date | 2016 |
| Headquarters | Houston, TX, Seattle, WA |
| Founders | Guy DiPierro, Ronald Martell |
| Revenue | Not publicly disclosed |
| Profits | Not publicly disclosed |
| Key Investors | RA Capital Management, Leaps by Bayer, Vertex Ventures HC |
| Industry | Biotechnology |
| Number of Employees | Approximately 30 |
| Subsidiaries | None known |
Early History
Indapta Therapeutics was established in 2016, founded by Guy DiPierro and Ronald Martell. The company launched with the goal of developing off-the-shelf, non-engineered cellular therapies to address the limitations inherent in traditional autologous cell therapies like CAR T-cells. Drawing from novel discoveries at institutions like Stanford University and UC Davis, Indapta pursued the development of G-NK cell therapies, focusing on their potent, epigenetically altered natural killer cells sourced from healthy donors.
Company Profile and Achievements
Indapta Therapeutics has developed a robust platform that utilizes G-NK cells. These cells, known for their exceptional ability to kill cancer cells and enhance antibody-dependent cellular cytotoxicity (ADCC), form the backbone of Indapta's therapeutic interventions. By coupling G-NK cells with FDA-approved monoclonal antibodies, Indapta provides a promising approach to treating hematologic and solid tumors. Significant achievements include:
- Successful preclinical studies showcasing the enhanced efficacy of G-NK cells when combined with monoclonal antibodies against multiple myeloma.
- Strategic collaborations, notably with Lonza for manufacturing processes and Sanofi for combined therapy exploration.
- Completion of multiple funding rounds, signaling investor confidence in its technology.
- Entry into clinical trials, including a pioneering study for multiple sclerosis, marking its expansion into autoimmune diseases.
Current Operations and Market Position
Indapta Therapeutics is actively conducting Phase 1 trials for its flagship product, IDP-023, targeting non-Hodgkin’s lymphoma and multiple myeloma, with promising early results. Its operations span from research and development to clinical testing, focusing on enhancing the applicability of g-NK cells beyond oncology into autoimmune disorders. Indapta holds a strategic edge with its scalable, cryopreserved therapeutic products that promise lower variability and heightened efficacy compared to traditional NK cell therapies. Its collaborations with key stakeholders, such as Sanofi, underscore its competitive positioning and potential impact across therapeutic landscapes.
Conclusion
Indapta Therapeutics stands at the forefront of next-generation cell therapies, driving innovation within the realms of cancer and autoimmune disease treatment. Through strategic partnerships and substantial investments, it is poised to advance its clinically significant G-NK cell platform into broader therapeutic territories. As the company progresses through clinical trials and expands its market reach, it is well-positioned to make a transformative impact in immunotherapy, potentially setting new industry standards and offering hope for conditions with high unmet needs.